Imatinib Krka

Imatinib, the active ingredient in Imatinib Krka, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets malignant cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumor, primarily in adult patients.

GNH USA supplies Imatinib Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Imatinib acts on abnormal tyrosine kinase signaling pathways that drive certain hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell burden and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and prolongs progression‑free survival. - Dermatofibrosarcoma protuberans (DFSP): induces tumor regression by blocking KIT signaling.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially around the ankles. - Muscle cramps: transient skeletal muscle discomfort. - Fatigue: generalized tiredness. - Diarrhea: loose stools, often self‑limiting. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced ejection fraction or congestive symptoms. - Pulmonary hypertension: increased pulmonary arterial pressure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemorrhage: unusual bleeding or bruising.

When prescribing Imatinib, clinicians should consider several safety precautions.

- Baseline blood counts: obtain CBC before initiating therapy. - Liver function: monitor transaminases regularly. - Cardiac assessment: evaluate for heart failure in at‑risk patients. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Drug interactions: review concomitant CYP3A4 inhibitors or inducers. - Store below 25°C: keep in the original pack, protect from moisture.

Imatinib interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib concentrations. - Potent CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrate drugs (e.g., midazolam, statins): may require dose adjustment. - QT‑prolonging agents (e.g., sotalol, quinidine): monitor cardiac rhythm. - Live attenuated vaccines: assess timing relative to therapy.